Dr Haren Vasavada
Previously, Haren served as the Head of New Targets and Therapeutics at Alexion Pharmaceuticals, Inc., where he led a new-target team that evaluated more than 150 pre-clinical and clinical stage opportunities, resulting in multiple licensing and collaboration agreements, and also led academic collaborations for early stage research programs. Prior to Alexion, he was Vice President, Process Science at Optherion, Inc. Haren began his career in the biopharmaceutical industry at Bayer, Inc., where he rose to the position of Director of Research in Bayer’s Department of Research Technologies, advancing a both small molecule and biologic drug candidates into product development.
Before his industry career, Haren was an associate research scientist in Yale University’s Department of Human Genetics. He received his PhD from the Indian Institute of Science in Bangalore and did his postdoctoral work at Yale University.